|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1225 NEW YORK AVE. NW |
Address2 | 8th floor |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 14108-12
|
||||||||
|
6. House ID# 300450000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jane Sheehan |
Date | 10/19/2018 3:30:50 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S.J.RES.63 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury, Secretary of Labor, and Secretary of Health and Human Services relating to "Short-Term, Limited Duration Insurance".
S.3411 - Affordable Medications Act - comprehensive legislation to address rising prescription drug prices
CURE High Drug Prices Act - prevent price gouging by pharmaceutical companies
S.3485 - Basic Health Program Expansion Act of 2018 - allow States to expand basic health programs to cover more low-income individuals at lower cost.
H.R.5977 - MOMMA's Act - improve Federal efforts with respect to the prevention of maternal mortality
H.R.6478 - Biosimilars Competition Act of 2018 - enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding biologic and biosimilar products
S.3194 - Capping Prescription Costs Act of 2018 - cap prescription drug cost-sharing to $250 per month for each enrolled individual, or $500 for each family starting in 2020
H.R.2889 - Closing Loopholes for Orphan Drugs Act - revise the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program
H.R.5942 - Health Equity and Accountability Act of 2018 - lobbied in support of entire bill; specifically lobbied in support of TITLE IV-IMPROVING HEALTH CARE ACCESS AND QUALITY - Subtitle C-Advancing Health Equity Through Payment And Delivery Reform.
H.R.2422 - Action for Dental Health Act of 2017 - HHS provides grants to improve essential oral health care for low-income and other underserved individuals by breaking down barriers to care
S.974 - CREATES Act of 2017 - facilitate the timely entry of lower-cost generic and biosimilar versions of drugs and biological products
S.Res.581 - A resolution authorizing the Senate Legal Counsel to represent the Senate in Texas v. United States, No. 4:18-cv-00167-O (N.D. Tex.)
Reducing Costs for Out-of-Network Services Act of 2018 - cap the amount that hospitals and physicians could charge uninsured patients and out-of-network patients who have individual market coverage
Surprise billing - draft legislation to prevent surprise medical billing of patients.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.6505 - Medicare Negotiation and Competitive Licensing Act - require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program
H.R.6823 - Supporting Positive Outcomes After Release Act - suspend, rather than terminate, an individuals eligibility for medical assistance under the State Medicaid plan while such individual is an inmate of a public institution
S.3330 - Medicare and Medicaid Protection Act of 2018 - prevent legislation privatizing Medicare, limiting federal funding for Medicaid, or decreasing benefits in Medicare or Medicare in reconciliation legislation
H.R. 6 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act - Section 5021, 5022 - H.R. 3192, the CHIP Mental Health Parity Act; Section 5031, 5032 - H.R. 4005, the Medicaid Reentry Act;
S.3462 - Improving Coverage for Substance Use Disorder Recovery Expansion Act - provide States with the option to provide medical assistance for substance use disorder treatment services to individuals; modification of IMD exclusion
H.R. 5797 - Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act - partial removal of IMD exclusion
H.R. 3891 -clarifying the authority of State Medicaid fraud and abuse control units to investigate and prosecute cases of Medicaid patient abuse and neglect in any setting
Oral health -Medicare dental benefit; Medicare coverage of medically necessary oral health care
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S.Amdt.3826 to S.Amdt.3695 - amends H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 - require HHS to submit to Congress a report on asthma control activities, include information on how states can use Medicaid funding to facilitate these activities, on public health and population level approaches to addressing environmental exposures, how health and housing can work together, and what HHS is doing to expand asthma housing and home-based related programs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Gremminger |
|
|
|
Jane |
Sheehan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
H.R.5414 - Help Separated Families Act of 2018 - entire legislation
S.3036 - Keep Families Together Act - entire legislation
H.R.3440 - Dream Act of 2017 - entire legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Gremminger |
|
|
|
Jane |
Sheehan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
S.3357 - Anti-Corruption and Public Integrity Act - anti-corruption, lobbying reform legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |